BestStocksBeta
Market closed · After hours · 5:42 PM ET
Last update: Oct 8, 2026, 5:17 PM ET
ResMed Inc.
$226.73▲ 0.33% today
After Hours

Why ResMed Inc. (RMD) stock moved

Updated Oct 8, 2026

ResMed Inc. (RMD) shares rose 0.3% to $226.73 as of October 8, 2026, a slight gain from the prior close of $225.98. BestStocks flagged the session as a major change for RMD. The move is tied to company news. Below, we break down what changed for RMD, why it matters for investors, how the stock reacted, and the catalysts on the calendar.

What happened

Company News

ResMed scheduled Q1 FY2027 earnings release for October 29, 2026, after NYSE close. Investors can mark earnings date to assess operational performance and guidance updates.

This summary describes the catalyst and move as first detected on Oct 1, 2026, 4:44 PM EDT; the stock has continued trading since, so the current price and percentage move (shown above) may be larger or smaller than the figures here.
NewsWeak confidence
Rel. volume
0.4×
Below Avg
Vs peers
—
No comparable peers
Market cap
$32.9B
New York Stock Exchange
Analyst target
$243
+7.0% vs price
Price chart
Sep 8 – Oct 8
NEF$218$224$230Sep 8Sep 16Sep 23Oct 1Oct 8
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details

What it means for ResMed Inc. investors

For ResMed Inc. investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Positive 0.3% session move; ResMed Inc. (RMD) moved +3.85% from $211.89 to $220.05 on 2026-08-10. Weighing against that: RMD moved -6.33% from $219.75 to $205.84 on 2026-07-08; New SEC filing — review for material disclosures. Wall Street's consensus price target sits at $242.70, implying +7.0% upside from $226.73. Over the past 90 days analysts logged 1 upgrade and 1 downgrade. BestStocks rates the overall signal quality weak (23/100). With earnings roughly 21 days out, the next report is the most likely near-term test of the move.

RMD price reaction

RMD last traded at $226.73, up $0.75 (+0.33%) from the previous close of $225.98. The session traded on 0.4× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $218.27 and $229.44, and it currently sits about 76% of the way up that band.

Bullish and bearish analyst opinions on ResMed Inc. (RMD)

The consensus analyst price target on ResMed Inc. (RMD) is $242.70, 7.0% above the recent $226.73. Over the past 90 days analysts logged 1 upgrade, 7 maintains, and 1 downgrade. Here is how the bullish and bearish cases on RMD line up.

The bullish case

  • Wall Street's consensus price target of $242.70 implies +7.0% upside from $226.73.
  • The Street's most bullish target is $300.00 (+32.3%).
  • 1 analyst upgrade in the past 90 days, most recently RBC Capital to Outperform (2026-09-15).
  • Positive 0.3% session move.
  • ResMed Inc. (RMD) moved +3.85% from $211.89 to $220.05 on 2026-08-10.

The bearish case

  • The most bearish analyst target is $213.00 (-6.1%).
  • 1 analyst downgrade in the past 90 days, most recently Citigroup to Neutral (2026-07-13).
  • RMD moved -6.33% from $219.75 to $205.84 on 2026-07-08.
Bull vs bear balanceNeutral / Mixed
BearishNeutralBullish

Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.

Analyst price targets and ratings are FMP consensus figures as of Oct 8, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.

Analyst expectations
Consensus target: $243+7.0%
↑ 1 upgrades= 7 maintains↓ 1 downgrades
RBC Capital upgraded to Outperform · 2026-09-15
SEC filings watch
DEF 14A2026-10-01
Annual proxy — exec compensation & governance
low
8-K2026-09-01
Material event — review for impact
high
8-K2026-08-17
Material event — review for impact
high
10-K2026-08-13
Annual financial report
high
Peer context
RMD+0.3%

Previous notable changes for RMD

Filings2026-10-01+0.0%
ResMed Inc. (RMD) filed its proxy statement (DEF 14A) on October 1, 2026, ahead of its upcoming shareholder meeting.
Material / Earnings2026-09-22-0.7%
RMD moved -100.00% from its $226.22 open to a $221.97 close on 2026-09-22.
Filings2026-09-01-3.6%
ResMed Inc. (RMD) filed a new 8-K on September 1, 2026. The specific content of the filing was not detailed in available sources.
Material / Earnings2026-09-01-3.6%
ResMed Inc. (RMD) moved -3.53% from $239.82 to $231.36 on 2026-09-01. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume was near its 5-day average, suggesting a routine decline without unusual selling pressure.

In-depth RMD event analyses

Permanent, dated analyses of RMD's most significant sessions.
Upcoming catalysts & outlook
Next earnings
2026-10-29 (est.)
in 21 days
10-K Annual Report (est.)
2027-08-13
Medium impact
Thesis shift
Neutral / Mixed
bullish signal
Risk level
Medium
from change events

Frequently asked questions about RMD

Why did ResMed Inc. (RMD) stock move?

RMD rose 0.3% to $226.73. The move coincided with the context summarized above, though no single company-specific catalyst was independently confirmed.

How much did RMD stock rise?

RMD gained 0.33% ($0.75) versus the prior close of $225.98, last trading at $226.73 on 0.4× average volume.

When is ResMed Inc.'s next earnings date?

RMD's next earnings report is estimated for 2026-10-29 — about 21 days away.

What is the analyst price target for RMD?

The consensus analyst price target for RMD is $242.70, about 7.0% above the current $226.73. Over the past 90 days, analysts recorded 1 upgrade, 7 maintains, and 1 downgrade.

How BestStocks tracks RMD

This page is generated automatically by BestStocks' change-detection system after company news was detected and verified against independent data sources. It draws on 20 tracked change events for RMD, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of October 8, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.

Data sources
FMP real-time & historical price dataCompany news feedsSEC EDGAR filingsAnalyst ratings & price targets (FMP)Earnings calendar (FMP)
Educational research tool — not personalized investment advice. Data may be delayed.